MindMed ‘s Plan to END the Opioid Epidemic (How MMED / MMEDF Could Make Billions)

Who’s next in line to Uplist to the Nasdaq? Numinus? Cybin? FieldTrip? ALL of them??
Today, I’ll be covering an article by Jeff Neilson published on The Psychedelic Stock Watch. In this article, Jeff outlines several stocks as contenders for an uplisting.

* Cybin Inc (CAN:CYBN / US:CLXPF) : Cybin is also one of the more successful companies in raising capital, having raised ~CAD$88.8 million (US$70 million) since going public last November and as we have been repeating on this channel, capital is a very important factor for the successful continuation and advancement of clinical trials.

*Field Trip Health (CAN:FTRP / US:FTRPF) : Field Trip Health shares some similarities with Cybin as an uplisting prospect. It has raised even more capital than Cybin, in excess of US$100 million, including its recent CAD$95 million bought deal financing (US$76 million) and Field Trip has also a price target of CAD$8.50 price target from Stifel GMP to its February 2021 high of CAD$8.25.

*Numinus Wellness (CAN:NUMI / US:LKYSF) : Numinus Wellness actually has a stronger following among retail investors than either Cybin or Field Trip. It was second only to MindMed as the volume leader among psychedelic stocks in the 2020 rally. It was also the second-best performer among all of the leading stocks in that rally, generating a 10X return at its 2020 peak.

However, these are not the only psychedelic stocks to peak Jeff Neilson’s eye.
He also mentions:

Mind Cure Health (CAN:MCUR / US:MCURF)
Mydecine Innovations Group (CAN:MYCO / US:MYCOF)
Bright Minds Biosciences (CAN:DRUG / US:BMBIF)
Small Pharma Inc( it hasn’t even started public trading YET)

Timestamps:
0:00 – Intro
1:55 – Cybin ( CYBN / CXPF )
6:13 – Field Trip Health ( FTRP / FTRPF )
9:05 – Numinus Wellness ( NUMI / LKYSF )
11:35 – Mindcure Health
12:08 – Mydecine ( MYCO /MYCOF )
12:34 – Bright Minds Biosciences ( DRUG / BMBIF )
13:10 – Small Pharma Inc.

Link to the article in question: https://psychedelicstockwatch.com/psychedelic-stock-news/the-next-psychedelic-stock-to-uplist-on-the-nasdaq?fbclid=IwAR3CgezfqtNHk0U3_YX5LYHDU2Y34jEFSTdNVGVchsKgR4CdEj58Q-lYcwk
Link to Cybin (CYBN) : https://www.cybin.com/
Link to Canacord: https://thetradingpriest.com/wp-content/uploads/2021/04/ResearchReport-1.pdf
Link to Numinus (NUMI): https://numinus.ca/
Link to Field Trip ( FTRP / FTRPF) : https://www.fieldtriphealth.com/

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #Cybin #Numi

Mydecine (OTC: MYCOF, NEO: MYCO) is an aspiring psychedelics medicine company that aims to use psilocybin, the active ingredient in magic mushrooms, to treat smoking addiction and PTSD. First, they are using pure psilocybin called MYCO-001, but eventually, Mydecine wants to use a proprietary, shorter-lasting compound called MYCO-004.

While Mydecine probably isn’t considered as being in the top tier of psychedelic researchers (yet at least), they recently have teamed up with Johns Hopkins University and Dr. Matthew Johnson, an institution and individual widely considered to be leaders in the field. With this partnership, Mydecine may become a leader among the “shroom stocks”.

Specifically, Mydecine and Johns Hopkins are joining forces to run phase 2 and 3 clinical trials treating smoking addiction with psilocybin, though they may expand their partnership in the future.

Is Mydecine (MYCO:NEO) (MYCOF: OTC ) one of the best penny stocks of 2021? Can magic mushrooms treat smoking addiction? Watch the episode to find out!

Waht do you guys think about the Mydecine partnering up with Johns Hopkins University?

Links:
https://uploads-ssl.webflow.com/5ee12ebc38f9e96f52217dd1/610efbd58b2b1755e49eb55b_MYCO_Presentation_8.6.21-compressed.pdf

https://www.hopkinsmedicine.org/profiles/details/matthew-johnson

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MYDECINE #MYCO #JOHNSHOPKINS